Grimm Christoph, Polterauer Stephan, Zeillinger Robert, Tempfer Clemens, Sliutz Gerhard, Reinthaller Alexander, Hefler Lukas A
Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.
Eur J Obstet Gynecol Reprod Biol. 2008 Apr;137(2):236-9. doi: 10.1016/j.ejogrb.2007.04.010. Epub 2007 Jun 1.
Prohibitin is an important antiproliferative protein inhibiting cell proliferation by blocking the G1/S transition of the cell cycle. Recent findings indicate that the presence of at least one mutant allele within a certain prohibitin gene polymorphism causes inactivation of bioactive RNA resulting in the loss of its pro-apoptotic function and a subsequent risk for malignant growth. Based on these findings we studied whether the presence of this prohibitin polymorphism increases the risk and worsens the prognosis of ovarian cancer in Caucasian women.
A polymorphism within the 3' untranslated region (UTR) of the prohibitin gene was evaluated by pyrosequencing in 136 Caucasian patients with epithelial ovarian cancer and 129 healthy Caucasian controls.
The wild-type C/C, heterozygous C/T, and the mutant T/T prohibitin genotype was found in 88 (64.7%), 46 (33.8%), and 2 (1.5%) patients with ovarian cancer and in 84 (65.1%), 39 (30.2%), and 6 (4.7%) healthy controls. Presence of at least one mutant allele of the prohibitin 3' UTR polymorphism was not associated with an increased risk of ovarian cancer as compared to healthy controls (P=0.9). No association was found between presence of the prohibitin 3' UTR polymorphism and the clinico-pathological parameters tumor stage, tumor grade, and patients' age at diagnosis. Presence of at least one mutant allele of the prohibitin 3' UTR polymorphism was not associated with disease-free and overall survival.
The prohibitin 3' UTR polymorphism was not associated with risk and prognosis of ovarian cancer in Caucasian women.
抑制素是一种重要的抗增殖蛋白，通过阻断细胞周期的G1/S转换来抑制细胞增殖。最近的研究结果表明，特定抑制素基因多态性中至少存在一个突变等位基因会导致生物活性RNA失活，从而丧失其促凋亡功能，并随后增加恶性生长的风险。基于这些发现，我们研究了这种抑制素多态性的存在是否会增加白种女性患卵巢癌的风险并恶化其预后。
通过焦磷酸测序法对136例白种上皮性卵巢癌患者和129例健康白种对照者的抑制素基因3'非翻译区（UTR）多态性进行评估。
在88例（64.7%）、46例（33.8%）和2例（1.5%）卵巢癌患者中发现野生型C/C、杂合子C/T和突变型T/T抑制素基因型，在84例（65.1%）、39例（30.2%）和6例（4.7%）健康对照者中也发现了相应基因型。与健康对照相比，抑制素3'UTR多态性中至少存在一个突变等位基因与卵巢癌风险增加无关（P=0.9）。未发现抑制素3'UTR多态性的存在与临床病理参数肿瘤分期、肿瘤分级及诊断时患者年龄之间存在关联。抑制素3'UTR多态性中至少存在一个突变等位基因与无病生存期和总生存期无关。
抑制素3'UTR多态性与白种女性卵巢癌的风险和预后无关。
